This information is for educational purposes only. It is not intended as medical advice. Always consult a qualified healthcare professional.
BORTEZOMIB BAXTER 3,5 MG POLVO PARA SOLUCION INYECTABLE EFG — Description, Dosage, Side Effects | PillsCard
OTC
BORTEZOMIB BAXTER 3,5 MG POLVO PARA SOLUCION INYECTABLE EFG
INN: BORTEZOMIB BAXTER
Data updated: 2026-04-18
Available in:
🇨🇿🇩🇪🇬🇧🇪🇸🇫🇷🇵🇹🇸🇰
Form
—
Dosage
—
Route
—
Storage
—
About This Product
User Reviews
Reviews reflect personal experiences and are not medical advice. Always consult your doctor.
Manufacturer
Baxter Holding B.V. (ES)
ATC Code
L01XG01
Source
CIMA_ES
(
ARTG
)
BORTEZOM in combination with melphalan and prednisone is indicated for the treatment of patients with previously untreated multiple myeloma who are not candidates for high dose chemotherapy.
BORTEZOM as part of combination therapy, is indicated for induction therapy prior to high dose chemotherapy with autologous stem cell rescue for patients under 65 years of age with previously untreated multiple myeloma.
BORTEZOM is also indicated for the treatment of multiple myeloma patients who have received at least one prior therapy, and who have progressive disease.
BORTEZOM in combination with rituximab, cyclophosphamide, doxorubicin and prednisone is indicated for the treatment of adult patients with previously untreated mantle cell lymphoma.
